A leading research-based biopharmaceutical company, Pfizer has announced that its Managing Director S Sridhar has resigned from the company. The company said in a regulatory filing.
S Sridhar has expressed his intention to retire early. The company stated that he would continue to serve as the MD until the identification, selection, and transition to the new leadership takes place.
The company said, “Sridhar made significant contributions to the growth of the company’s portfolio, presence across India, and reach to patients who have benefited from access to Pfizer therapies.”
Although the effective date of S Sridhar’s resignation will be announced later after discussions between Sridhar and Pfizer’s board of directors.
As the Country Manager and Managing Director of the third-largest MNC pharmaceutical company in India, S Sridhar has led Pfizer Inc’s commercial function in the country. Each day, he woke up with a mission—to positively impact public health and make medicines accessible to patients across the country.
S Sridhar has led several key leadership positions in Pfizer. He has been associated with the organization for 14 years including serving as the Chief Financial Officer for eight years.
He started his career as a Chartered Accountant, has served as an Executive Committee member and the chair of the Pricing and Taxation Committee of OPPI (Organisation of Pharmaceutical Producers of India), and chairs the Pharma Committee of FICCI (Federation of Indian Chambers of Commerce and Industry).
Pfizer applies science and global resources to deliver innovative therapies that extend and significantly improve lives. Every day, the company colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time.
